We can take advantage of the evolutionarily conserved pathways, proteins, and metabolites as well as the available X-ray structures of MESH1 [13, 14], to design MESH1 inhibitors and repress tumor proliferation as novel therapeutics. This evidence concerns the gene HDDC3 and neoplasm.